Function and organ preservation in adult cancers of the head and neck

Expert Review of Anticancer Therapy

Volumn 7, Issue 3, 2007, Pages 361-371

  Mehta, Par S ^a   Harrison, Louis B ^a,b,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Institute for Head and Neck and Thyroid Cancer   (United States)

Author keywords

Base of tongue; Function preservation; Head and neck cancer; Hypopharynx; Larynx; Organ preservation; Oropharynx; Radiation therapy; Xerostomia

Indexed keywords

AMIFOSTINE; CETUXIMAB; CISPLATIN; FLUOROURACIL;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; ESTHETICS; FISTULA; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; HYPOPHARYNX CARCINOMA; LARYNGECTOMY; LARYNX CANCER; LASER SURGERY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OROPHARYNX CARCINOMA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PROGNOSIS; REVIEW; SALIVATION; SPEECH; SURGICAL TECHNIQUE; SWALLOWING; SYSTEMATIC REVIEW; TONGUE CARCINOMA; VISION; XEROSTOMIA;

CARCINOMA; CARCINOMA IN SITU; DEGLUTITION DISORDERS; DISEASE MANAGEMENT; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGAN SPECIFICITY; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; SALVAGE THERAPY; SPEECH DISORDERS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TONGUE NEOPLASMS; XEROSTOMIA;

EID: 33947615332     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.3.361     Document Type: Review

References (94)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin, 56, 106-130 (2006).
2. Harrison LB, Sessions RB, Hong WK. Head and Neck Cancer: A Multidisciplinary Approach (2nd Edition). Lippincott Williams & Wilkins, PA, USA (2004).
3. Leon X, Quer M, Orus C et al. Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck 22(7), 680-686 (2000).
4. Mendenhall WM, Amdur RJ, Morris CG et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J. Clin. Oncol. 19, 4029-4036 (2001).
5. Steiner W. Results of curative laser microsurgery of laryngeal carcinomas. Am. J. Otholaryngol. 14, 116-121 (1993).
6. Leibovitch I, Huilgol SC, Selva D et al. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years. J. Am. Acad. Dermatol. 53(3), 445-451 (2005).
7. Iyer S, Bowes L, Kricorian G et al. Treatment of basal cell carcinoma with the pulsed carbon dioxide laser: a retrospective analysis. Dermatol. Surg. 30(9), 1214-1218 (2004).
8. Fitzpatrick PJ. Skin cancer of the head - treatment by radiotherapy. J. Otolaryngol. 13(4), 261-266 (1984).
9. Fitzpatrick PJ. Cancer of the lip. J. Otolaryngol. 13(1), 32-36 (1984).
10. Kramer S, Gelber RD, Snow JB et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 10(1), 19-30 (1987)
11. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350(19), 1945-1952 (2004).
12. Cooper JS, Pajak TF, Forastiere AA et aL. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
13. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squasnous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 7-16 (2000).
14. Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21(1), 92-98 (2003).
15. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338(25), 1798-1804 (1998).
16. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N. Engl. J. Med. 324(24), 1685-1690 (1991).
17. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349(22), 2091-2098(2003).
18. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. nATL Cancer Inst. 88(13), 890-899 (1996).
19. Lefebvre JL, Chevalier D, Luboinski B et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the Phase III EORTC 24891 trial. j. Clin. OncoL. 22, S14 (2004).
20. Calais DF, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J. Clin. Oncol. 22(1), 69-76 (2004).
21. List MA, Stracks J, Colangelo L et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment. J. Clin. Oncol. 18, 877-884 (2000).
22. DeSanto LW, Olsen KD, Perry WC et al. Quality of life after surgical treatment of cancer of the larynx. Ann. Otol. Rhinol. Laryngol. 104, 763-769 (1995).
23. Hintz BL, Kagan AR, Nussbaum H et al. A 'watchful waiting' policy for in situ carcinoma of the vocal cords. Arch. Otolaryngol. 107(12), 746-751 (1981).
24. Flint PW. Minimally invasive techniques for management of early glottic cancer. Otolaryngol. Clin. North Am. 35, 1055-1066 (2002).
25. Rogerson AR, Clark KF, Bandi SR et al. Voice and healing after vocal fold epithelium removal by C02 laser vs. microlaryngeal stripping. Otolaryngol. Head Neck Surg. 115(4), 352-359 (1996).
26. Spayne JA, Warde P, O'Sullivan B et al. Carcinoma-in-situ of the glottic larynx: results of treatment with radiation therapy. Int. J. Radiat. Biol. Phys. 49(5), 1235-1238 (2001).
27. Le QT, Takamiya R, Shu HK et al. Treatment results of carcinoma in situ of the glottis: an analysis of 82 cases. Arch. Otolaryngol. Head Neck Surg. 126(11), 1305-1312 (2000)
28. Smitt MC, Goffinet DR. Radiotherapy for carcinoma-in-situ of the glottic larynx. Int. J. Radiat. Oncol. Biol. Phys. 28(1), 251-255 (1994).
29. 2 laser for surgical management of glottic carcinoma in situ. Laryngoscope 110(7), 1215-1221 (2000).
30. Peretti G, Piazza C, Bolzoni A et al. Analysis of recurrences in 322 Tis, T1, or T2 glottic carcinomas treated by carbon dioxide laser. Ann. Otol. Rhinol. Laryngol. 113(11), 853-858 (2004).
31. 2 laser cordectomy for early glottic carcinoma. Laryngoscope 116(1), 101-105 (2006).
32. Ledda GP, Puxeddu R. Carbon dioxide laser microsurgery for early glottic carcinoma. Otolaryngol. Head Neck Surg. 134(6), 911-915 (2006).
33. Ossoff R, Sisson G, Shapsay S et al. Endoscopic management of selected early vocal cord carcinoma. Ann. Otol. Rhinol. Laryngol. 94, 560-563 (1985).
34. Steiner W, Ambrosch P, Rodel RM et al. Impact of anterior commissure involvement on local control of early glottic carcinoma treated by laser microresection. Laryngoscope 114(8), 1485-1491 (2004).
35. Mendenhall WM, Wening JW, Hinerman RW et al. Management of T1-T2 glottic carcinomas. Cancer 100(9), 1786-1792 (2004).
36. Warde P, O'Sullivan B, Bristow RG et al. T1-T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int. J. Radiat. Oncol. Biol. Phys. 41, 347-353(1998).
37. Mendenhall WM, Amdur RJ, Morris CG et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J. Clin. Oncol. 19, 4029-4036 (2001).
38. Thariat J, Bruchon Y, Bonnetain F et al. Conservative treatment of early glottic carcinomas with exclusive radiotherapy. Cancer Radiother. 8(5), 288-296 (2004).
39. Cellai E, Frata P, Magrini SM et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1 NO disease. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1378-1386 (2005).
40. Yamazaki H, Nishiyama K, Tanaka E et al. Radiotherapy for early glottic carcinoma (T1NOMO): results of prospective randomized study of radiation fraction size and overall treatment time. Int. J. Radiat. Oncol. Biol. Phys. 64(1), 77-82 (2006).
41. Yu E, Shenouda G, Beaudet MP et al. Impact of radiation therapy fraction size on local control of early glottic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37(3), 587-591 (1997).
42. Delsupehe KG, Zink I, Lejaegere M et al. Voice quality after narrow margin laser cordectomy compared with laryngeal irradiation. Otolaryngol. Head Neck Surg. 121, 528-533 (1999).
43. McGuirt WF, Blalock D, Koufman JA et al. Comparative voice results after laser resection or irradiation of T1 vocal cord carcinoma. Arch. Otolaryngol. Head Neck Surg. 120, 951-955 (1994).
44. Verdonck de Leeuw, IM, Keus RB, Hilgers FJ et al. Consequences of voice impairment in daily life for patients following radiotherapy for early glottic cancer: voice quality, vocal function, and vocal performance. Int. J. Radiat. Oncol. Biol. Phys. 44, 1071-1078 (1999).
45. Frata P, Cellai E, Magrini SM et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2NO disease. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1387-1394 (2005).
46. Spector JG, Sessions DG, Chao KSC et al. Management of stage II (T2NOMO) glottic carcinoma by radiotherapy and conservation surgery. Head Neck 21, 116-123 (1999).
47. Fein DA, Mendenhall WM, Parsons JT et al. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int. J. Radiat. Oncol. Biol. Phys. 25(4), 605-611 (1993).
48. Garden AS, Forster K, Wong PF et al. Results of radiotherapy for T2NO glottic carcinoma: does the "2" stand for twice-daily treatment? Int. J. Radiat. Oncol. Biol. Phys. 55, 322-328 (2003).
49. Fein DA, Hanlon AL, Lee WR et al. Neck failure in T2NO squamous cell carcinoma of the true vocal cords: the Fox Chase experience and review of the literature. Am. J. Clin. Oncol. 20(2), 154-157 (1997).
50. Sessions DG, Lenox J, Spector GJ. Supraglottic laryngeal cancer: analysis of treatment results. Laryngoscope 115 (8), 1402-1410 (2005).
51. Bocca E. Surgical management of supraglottic cancer and its lymph node metastases in a conservative perspective. Ann. Otol. Rhinol. Laryngol. 100(4), 261-267 (1991).
52. Orus C, Leon X, Vega M et al. Initial treatment of the early stages (I, II) of supraglottic squamous cell carcinoma: partial laryngectomy versus radiotherapy. Eur. Arch. Otorhinolaryngol. 257(9), 512-516 (2000).
53. Mendenhall WM, Parsons JT, Stringer SP et al. Carcinoma of the supraglottic larynx: a basis for comparing the results of radiotherapy and surgery. Head Neck 12(3), 204-209(1990).
54. Richard JM, Sancho-Garnier H, Pessey JJ et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 34, 224-228 (1998).
55. Foote RL, Foote RT, Brown PD et al. Organ preservation for advanced laryngeal carcinoma. Head Neck 28(8), 689-696 (2006).
56. Pfister DG, Strong E, Harrison L et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J. Clin. Oncol. 9(5), 850-859 (1991).
57. Gilbert J, Forastiere AA. Organ preservation for cancer of the larynx: current indications and future directions. Semin. Radiat. Oncol. 14(2), 167-177 (2004).
58. Sherman EJ, Fisher SG, Aliff TB et al. TALK score: validation for a tool for predicting larynx preservation (LP) outcomes. Proc. Am. Soc. Clin. Oncol. 22, 1999 (2003).
59. Spaulding MB, Fischer S, Wold G et al. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J. Clin. Oncol. 12, 1592-1599 (1994).
60. Urba S, Wolf G, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J. Clin. Oncol. 24(4), 593-598 (2006).
61. Pfreunder L, Hoppe F, Willner J et al. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas - a possibility for organ preservation. Radiother. Oncol. 68(2), 163-170 (2003).
62. Majem M, Mesia R, Manos M et al. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma. Laryngoscope 116(9), 1651-1656 (2006).
63. Knab BR, Salama JK, Stenson KM et al. Definitive chemoradiothetapy for T4 laryngeal squarnous cell carcinomas. Int. J. Radiat. Oncol. Biol, Phys. 66(3S), S14 (2006).
64. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
65. Holsinger FC, Motamed M, Garcia D et al. Resection of selected invasive squamous cell carcinoma of the pyriform. sinus by means of the lateral pharyngotomy approach: the partial lateral pharyngectomy. Head Neck 28(8), 705-711 (2006).
66. Laccourreye O, Merite-Drancy A, Brasnu D et al. Supracricoid hemilaryngopharyngectomy in selected pyriform. siuns carcinoma staged as T2. Laryngoscope 103(12), 1373-1379 (1993).
67. Kania R, Hans S, Garcia D et al. Supracricoid hemilaryngopharyngectomy in patients with invasive squamous cell carcinoma of the pyrifor siuns. Part II: incidence and consequences of local recurrence. Ann. Otol. Rhinol. Laryngol. 114(2), 95-104 (2005).
68. Mendenhall WM, Parsons JT, Stringer SP et al. Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus. An alternative to conservation surgery. Int. J. Radiat. Oncol. Biol. Phys. 27, 1017-1027 (1993).
69. Amdur RJ, Mendenhall WM, Stringer SP et al. Organ preservation with radiotherapy for T1-T2 carcinoma of the pyrifirm sinus. Head Neck 23, 353-362 (2001).
70. Nakamura K, Shiotama Y, Sasaki T et al. Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int. J. Radiat. Oncol. Biol. Phys. 62(3), 680-683 (2005).
71. Zelefsky MJ, Kraus DH, Pfister DG et al. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck 18, 405-411 (1996).
72. Urba SG, Moon J, Giri PG et al. Organ preservation for advanced resectable, cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J. Clin. Oncol. 23, 88-95 (2005).
73. Leon X, Quer M, Orus C et al. Results of an organ preservation protocol with induction chemotherapy and radiotherapy in patients with advanced pyriform sinus carcinoma. Eur. Arch. Otorhinolaryngol. 259(1), 32-36 (2002).
74. Ozer E, Grecula JC, Agrawal A et al. Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 132(4), 385-389 (2006).
75. Harrison LB, Ferlito A, Shaha AR et al. Current philosophy on the management of cancer of the base of tongue. Oral Oncol. 39, 101-105 (2003).
76. Harrison LB, Zelefsky MJ, Armstrong JG et al. Performance status after treatment for squamous cell cancer of the base of tongue - a comparison of primary radiation therapy versus primary surgery. Int. J. Radiat. Oncol. Biol. Phys. 30(4), 953-957 (1994).
77. Nisi KW, Foote RL, Bonner JA et al. Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved local-regional disease control compared with surgery alone. Int. J. Radiat. Oncol. Biol. Phys. 41(2), 371-377 (1998).
78. Kraus DH, Vastola AP, Huvos AG et al. Surgical management of squamous cell carcinoma of the base of tongue. Am. J. Surg. 166, 384-388 (1993).
79. Housset M, Baillet F, Dessard-Diana B et al. A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. Int. J. Radiat. Oncol. Biol. Phys. 13, 511-516 (1987).
80. Harrison LB, Lee HJ, Pfister DG et al. Long term results of primary radiotherapy with/without neck dissection for squamous cell cancer of the base of tongue. Head Neck 20(8), 668-673 (1998).
81. Mendenhall WM, Stringer SP, Amdur RJ et al. Is radiation therapy a preferred alternative to surgery for squamous cell carcinoma of the base of tongue? J. Clin. Oncol. 18(1), 35-42 (2000).
82. Hu K, Harrison LB. Point/counterpoint. Brachytherapy versus intensity-modulated radiation therapy in the management of base of tongue cancers. Brachytherapy 4, 1-4 (2005).
83. Lee N. Point/counterpoint. Brachytherapy versus intensity-modulated radiation therapy in the management of base of tongue cancers. Brachytherapy 4, 5-7 (2005).
84. Pfister DG, Harrison LB, Strong EW et al. Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiotherapy. J. Clin. Oncol. 13(3), 671-680 (1995).
85. Fallai C, Bolner A, Signor M et al. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori 92(1), 41-54 (2006).
86. Semrau R, Meuller RP, Stuetzer H et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 64(5), 1308-1316(2006).
87. Beckmann GK, Hoppe F, Pfreundner L et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27(1), 36-43 (2005).
88. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24, 1072-1078 (2006).
89. Deutsch I, Hu K, Culliney B et al. Accelerated radiation therapy and concurrent chemotherapy for advanced oropharyngeal cancer. Int. J. Radiat. Biol. Phys. 66(3), S456-S457 (2006).
90. Dirix P, Nuyts S, Van den Bogaery W. Radiation-induced xerostomia in patients with head and neck cancer. Cancer 107, 2525-2534(2006).
91. Eisbruch A, Ten Haken RK, Kim HM et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck caner. Int. J. Radiat. Oncol. Biol. Phys. 45(3), 577-587 (1999).
92. Lee NY, de Arruda FF, Puri DR et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66(4), 966-974 (2006).
93. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18(19), 3339-5345(2000).
94. Sasse AD, Clark LG, Sasse EC et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 64(3), 784-791 (2006).